Best of ASCO - 2014 Annual Meeting

 

Welcome

Myelodysplastic Syndromes (MDS)

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A pilot trial of anti-KIR antibody with or without 5-azacitidine for myelodysplastic syndrome.

Fevzi Firat Yalniz

7067

Association of early intervention in transfusion independent (TI) patients (Pts) with lower-risk myelodysplastic syndromes (MDS) treated with attenuated doses of hypomethylating agents (HMAs) with high response rates and long duration of response.

Mahesh Swaminathan

7001

Characteristics and outcomes of myelodysplastic syndrome (MDS) with chromosome (chr)3q abnormalities.

Mansour Alfayez

7069

Characterization and similarity assessment of a pegfilgrastim biosimilar MYL-1401H.

Praveen Kallamvalliillam Sankaran

e19028

Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.

Uwe Platzbecker

7018

Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.

Paolo Strati

7064

Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II clinical trial.

Gabriela Sanchez-Petitto

7066

Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.

Chun Yew Fong

TPS7082

Psychological distress in myelodysplastic syndromes.

Jaxon Vallely

e19027

PU.1 and JDP2 expression in myelodysplastic syndromes to predict treatment response and leukemia transformation.

Kristian Boasman

7065

The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome per 2017 WHO guideline compared to de novo MDS.

Omar Alkharabsheh

e19026

The impact of clonal size on the revised international prognostic scoring system (R-IPSS) in myelodysplastic syndromes (MDS) with a single cytogenetic abnormality.

Omar Alkharabsheh

7068

Variability in the extent of del(5q) and its clinical implication in myelodysplastic syndromes (MDS).

Zuzana Zemanova

e19025